Engitix Announces $54M Series A Financing And A Strategic Collaboration With Dompé Farmaceutici Using Exscalate’s Ai Supercomputing Power To Advance Its Drug Discovery Pipeline In Fibrosis And Cancer

Jan 19, 2022•over 3 years ago

Amount Raised

$54 Million

Round Type

series a

London

Description

Engitix Ltd (‘Engitix’), a biopharmaceutical company with a pioneering and proprietary human extracellular matrix (ECM) drug target discovery platform today announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A (“Dompé”).

Company Information

Company

Engitix Ltd

Location

London, Ontario, Canada

About

Engitix is developing a portfolio of internal & partnered drug discovery programmes in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) platform. The use of more physiologically relevant human in vitro models is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. It has partnerships with Dompé farmaceutici and Takeda, and a previous partnership with Morphic Therapeutics. Engitix was founded in 2016 to commercialise cutting-edge research at the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL). The company is headquartered in Westworks, White City Place, London, UK. A private company, Engitix investors include Netherton Investments, a fund investing on behalf of Mike Platt, and Dompé farmaceutici, an Italian and US-based biopharmaceutical company. For more information, please visit www.engitix.com Follow us on LinkedIn

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech